WallStSmart

Diebold Nixdorf, Incorporated (DBD)vsShopify Inc (SHOP)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Shopify Inc generates 243% more annual revenue ($13.27B vs $3.87B). SHOP leads profitability with a 14.5% profit margin vs 2.9%. DBD trades at a lower P/E of 21.5x. SHOP earns a higher WallStSmart Score of 65/100 (B-).

DBD

Buy

54

out of 100

Grade: C-

Growth: 6.0Profit: 5.5Value: 5.3Quality: 5.0
Piotroski: 4/9Altman Z: 1.57

SHOP

Strong Buy

65

out of 100

Grade: B-

Growth: 10.0Profit: 7.5Value: 4.7Quality: 8.5
Piotroski: 3/9Altman Z: 6.69
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for DBD.

SHOPUndervalued (+23.2%)

Margin of Safety

+23.2%

Fair Value

$152.24

Current Price

$169.52

$17.28 discount

UndervaluedFair: $152.24Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DBD2 strengths · Avg: 8.0/10
Price/BookValuation
2.3x8/10

Reasonable price relative to book value

EPS GrowthGrowth
34.2%8/10

Earnings expanding 34.2% YoY

SHOP5 strengths · Avg: 10.0/10
Market CapQuality
$221.95B10/10

Mega-cap, among the largest globally

Revenue GrowthGrowth
33.7%10/10

Revenue surging 33.7% year-over-year

EPS GrowthGrowth
68.1%10/10

Earnings expanding 68.1% YoY

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
6.6910/10

Safe zone — low bankruptcy risk

Areas to Watch

DBD4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
1.7%4/10

1.7% revenue growth

Altman Z-ScoreHealth
1.574/10

Distress zone — elevated risk

Profit MarginProfitability
2.9%3/10

2.9% margin — thin

Debt/EquityHealth
1.143/10

Elevated debt levels

SHOP4 concerns · Avg: 3.3/10
PEG RatioValuation
1.734/10

Expensive relative to growth rate

Price/BookValuation
17.2x4/10

Trading at 17.2x book value

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

P/E RatioValuation
119.0x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : DBD

The strongest argument for DBD centers on Price/Book, EPS Growth.

Bull Case : SHOP

The strongest argument for SHOP centers on Market Cap, Revenue Growth, EPS Growth. Revenue growth of 33.7% demonstrates continued momentum.

Bear Case : DBD

The primary concerns for DBD are Revenue Growth, Altman Z-Score, Profit Margin. Thin 2.9% margins leave little buffer for downturns.

Bear Case : SHOP

The primary concerns for SHOP are PEG Ratio, Price/Book, Piotroski F-Score. A P/E of 119.0x leaves little room for execution misses.

Key Dynamics to Monitor

DBD profiles as a value stock while SHOP is a growth play — different risk/reward profiles.

SHOP carries more volatility with a beta of 2.63 — expect wider price swings.

SHOP is growing revenue faster at 33.7% — sustainability is the question.

SHOP generates stronger free cash flow (654M), providing more financial flexibility.

Bottom Line

SHOP scores higher overall (65/100 vs 54/100) and 33.7% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Diebold Nixdorf, Incorporated

TECHNOLOGY · SOFTWARE - APPLICATION · USA

Diebold Nixdorf, Incorporated provides connected commerce solutions to financial institutions and retailers in Western Europe, Eastern Europe, Asia, the Middle East, Africa, the United States, Canada, Mexico and Latin America. The company is headquartered in North Canton, Ohio.

Shopify Inc

TECHNOLOGY · SOFTWARE - APPLICATION · USA

Shopify Inc., a commerce company, offers a commerce and service platform in Canada, the United States, the United Kingdom, Australia, Latin America, and internationally. The company is headquartered in Ottawa, Canada.

Want to dig deeper into these stocks?